Bio-Rad Laboratories, Inc.
BIO-B
Last
—
Day
—
1y
-9.5%
5y
+300.4%
52w
-55.4%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0425d
EMA 21
296.98
EMA 50
301.78
EMA 200
385.96
20d high
+0.0%
5y high
-55.4%
5y range
41th
Positions held
Your positionsBIO-B isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
37
Hold
swing
Signal
Strong Buy
Target
$403.46
Stop
$346.66
Stop distance
—
Target vs last
—
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
Bull case
- Bio-Rad Laboratories operates in the medical devices industry, which is experiencing growth due to increasing healthcare demands and technological advancements.
- Revenue increased by 10% compared to the prior quarter, reaching $651 million.
- The operating margin expanded to 11.2%, indicating improved efficiency in operations.
Bear case
- Despite recent growth, Bio-Rad's trailing P/E ratio of 46.27 suggests the stock may be overvalued compared to industry peers.
- The company reported a net income loss of $527.1 million in Q1 2026.
- Revenue growth has been negative at -0.1%, indicating potential challenges in sustaining sales momentum.
Fundamentals
| Market cap | $9.76B | Enterprise value | $9.51B | Trailing P/E | 46.27 | Forward P/E | — |
| PEG | 4.23 | Price / book | 1.36 | Beta | 1.07 | Dividend yield | 0.00% |
| Revenue growth | -0.1% | Earnings growth | 18.7% | Gross margin | 52.0% | Operating margin | 11.2% |
| Profit margin | 8.6% | ROE | 3.1% | ROA | 1.7% | Debt / equity | 0.19 |
| Current ratio | 3.14 | Free cash flow | $283.19M | Analyst recommendation | none | Mean target | — |
| 52w high | $365.08 | 52w low | $244.54 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $651M | $592M | $693M | $653M | $652M | — |
| Op margin | 11.2% | 5.8% | 7.8% | 9.8% | 11.8% | — |
| Net income | $371M | -$527M | $720M | -$342M | $318M | — |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | — |
| Gross profit | $346M | $309M | $345M | $343M | $345M | — |
| Operating income | $72.6M | $34.1M | $53.9M | $63.9M | $77.1M | — |
- Revenue +10% vs prior quarter ($651M vs $592M).
- Gross margin 53.1% (was 52.3% prior quarter).
- Operating margin expanded to 11.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | — |
| Op margin | 8.5% | 10.5% | 12.6% | 17.0% | — |
| Net income | $760M | -$1.8B | -$637M | -$3.6B | — |
| Gross margin | 51.9% | 53.7% | 53.4% | 55.9% | — |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | — |
| Operating income | $219M | $269M | $338M | $475M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
No headlines.
Price (daily)
Full chart · RSI · MACD · patternsBIO-B · daily+39.9% over 10 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin